Bristol Myers Squibb has entered into an agreement with BioNTech for the global co-development and co-commercialisation of the latter’s bispecific PD-L1/VEGF-A antibody, BNT327. Through the deal, which involves a US$1.5 B upfront payment and up to US$7.6 B in milestones, the companies will jointly develop BNT327 which is currently being evaluated for multiple solid tumour types, including non-small cell lung cancer and small cell lung cancer. The deal marks yet another high-profile agreement in the PD-1/VEGF space, as key players in the industry such as Pfizer and Merck & Co. race to bring a new immunotherapy to market.